Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds
- PMID: 17018562
- PMCID: PMC2597910
- DOI: 10.1136/jmg.2006.045153
Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds
Abstract
Background: The major determinant of age of onset in Huntington's disease is the length of the causative triplet CAG repeat. Significant variance remains, however, in residual age of onset even after repeat length is factored out. Many genetic polymorphisms have previously shown evidence of association with age of onset of Huntington's disease in several different populations.
Objective: To replicate these genetic association tests in 443 affected people from a large set of kindreds from Venezuela.
Methods: Previously tested polymorphisms were analysed in the HD gene itself (HD), the GluR6 kainate glutamate receptor (GRIK2), apolipoprotein E (APOE), the transcriptional coactivator CA150 (TCERG1), the ubiquitin carboxy-terminal hydrolase L1 (UCHL1), p53 (TP53), caspase-activated DNase (DFFB), and the NR2A and NR2B glutamate receptor subunits (GRIN2A, GRIN2B).
Results: The GRIN2A single-nucleotide polymorphism explains a small but considerable amount of additional variance in residual age of onset in our sample. The TCERG1 microsatellite shows a trend towards association but does not reach statistical significance, perhaps because of the uninformative nature of the polymorphism caused by extreme allele frequencies. We did not replicate the genetic association of any of the other genes.
Conclusions: GRIN2A and TCERG1 may show true association with residual age of onset for Huntington's disease. The most surprising negative result is for the GRIK2 (TAA)(n) polymorphism, which has previously shown association with age of onset in four independent populations with Huntington's disease. The lack of association in the Venezuelan kindreds may be due to the extremely low frequency of the key (TAA)(16) allele in this population.
Conflict of interest statement
Competing interests: None.
Similar articles
-
The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease.Neurogenetics. 2006 Mar;7(1):27-30. doi: 10.1007/s10048-005-0023-z. Epub 2005 Dec 21. Neurogenetics. 2006. PMID: 16369839
-
TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease.Biochem Biophys Res Commun. 2012 Aug 3;424(3):404-8. doi: 10.1016/j.bbrc.2012.06.120. Epub 2012 Jul 3. Biochem Biophys Res Commun. 2012. PMID: 22771793 Free PMC article.
-
Modulation of age at onset in Huntington's disease and spinocerebellar ataxia type 2 patients originated from eastern India.Neurosci Lett. 2003 Jul 17;345(2):93-6. doi: 10.1016/s0304-3940(03)00436-1. Neurosci Lett. 2003. PMID: 12821179
-
Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease?Mech Ageing Dev. 2006 Feb;127(2):208-12. doi: 10.1016/j.mad.2005.09.012. Epub 2005 Nov 7. Mech Ageing Dev. 2006. PMID: 16274727 Review.
-
Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.Lancet Neurol. 2020 Nov;19(11):930-939. doi: 10.1016/S1474-4422(20)30343-4. Lancet Neurol. 2020. PMID: 33098802 Review.
Cited by
-
Huntington's disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads database.BMC Neurol. 2012 Jun 28;12:47. doi: 10.1186/1471-2377-12-47. BMC Neurol. 2012. PMID: 22741533 Free PMC article.
-
Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.J Neurol. 2019 Mar;266(3):551-564. doi: 10.1007/s00415-018-8940-6. Epub 2018 Jun 28. J Neurol. 2019. PMID: 29956026 Review.
-
ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease.J Mol Med (Berl). 2008 Apr;86(4):485-90. doi: 10.1007/s00109-007-0299-6. Epub 2008 Mar 8. J Mol Med (Berl). 2008. PMID: 18327563
-
Modification of Huntington's disease by short tandem repeats.Brain Commun. 2024 Jan 23;6(2):fcae016. doi: 10.1093/braincomms/fcae016. eCollection 2024. Brain Commun. 2024. PMID: 38449714 Free PMC article.
-
Glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) gene polymorphism (rs4998386) and Parkinson's disease susceptibility: A meta-analysis.Aging Med (Milton). 2019 Jul 23;2(3):174-183. doi: 10.1002/agm2.12075. eCollection 2019 Sep. Aging Med (Milton). 2019. PMID: 31942532 Free PMC article.
References
-
- Bates G, Harper P, Jones L.Huntington's disease, (3rd edn. Oxford, UK: Oxford University Press 2002
-
- Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 199372971–983. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous